{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:54:55Z","timestamp":1789584895194,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100031645","name":"Novartis Farma s.p.a.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031645","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03383-5","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:10:51Z","timestamp":1760343051000},"page":"5931-5949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion"],"prefix":"10.1007","volume":"42","author":[{"given":"Salvatore","family":"Tafuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secondo","family":"Lastoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Panzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cingarlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Filice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maccauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Partelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"1","key":"3383_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115\u201354. https:\/\/doi.org\/10.1007\/s12022-022-09708-2.","journal-title":"Endocr Pathol"},{"key":"3383_CR2","volume-title":"WHO classification of tumours of endocrine organs","author":"RV Lloyd","year":"2017","unstructured":"Lloyd RV, Rosai J, Osamura RY, Kloppel G. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC; 2017.","edition":"4"},{"issue":"2","key":"3383_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182\u20138. https:\/\/doi.org\/10.1111\/his.13975.","journal-title":"Histopathology"},{"issue":"7","key":"3383_CR4","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304.","journal-title":"Ann Oncol"},{"issue":"2","key":"3383_CR5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12020-013-9910-5","volume":"44","author":"G Tamagno","year":"2013","unstructured":"Tamagno G, Sheahan K, Skehan SJ, et al. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor. Endocrine. 2013;44(2):504\u20139. https:\/\/doi.org\/10.1007\/s12020-013-9910-5.","journal-title":"Endocrine"},{"key":"3383_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060910","author":"L Magi","year":"2019","unstructured":"Magi L, Mazzuca F, Rinzivillo M, et al. Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8060910.","journal-title":"J Clin Med"},{"key":"3383_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102803","volume":"129","author":"F Panzuto","year":"2024","unstructured":"Panzuto F, Lamarca A, Fazio N. Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors. Cancer Treat Rev. 2024;129:102803. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102803.","journal-title":"Cancer Treat Rev"},{"issue":"10446","key":"3383_CR8","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/s0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase\u00a03 study. Lancet. 2024;403(10446):2807\u201317. https:\/\/doi.org\/10.1016\/s0140-6736(24)00701-3.","journal-title":"Lancet"},{"issue":"2","key":"3383_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000534035","volume":"114","author":"NC Helderman","year":"2024","unstructured":"Helderman NC, Suerink M, Kilin\u00e7 G, van den Berg JG, Nielsen M, Tesselaar MET. Relation between WHO classification and location- and functionality-based classifications of neuroendocrine neoplasms of the digestive tract. Neuroendocrinology. 2024;114(2):120\u201333. https:\/\/doi.org\/10.1159\/000534035.","journal-title":"Neuroendocrinology"},{"key":"3383_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031447","author":"O Rogoza","year":"2022","unstructured":"Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of somatostatin signalling in neuroendocrine tumours. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23031447.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3383_CR11","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1111\/j.1582-4934.2010.01125.x","volume":"14","author":"M Cakir","year":"2010","unstructured":"Cakir M, Dworakowska D, Grossman A. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1\u2013molecular pathways. J Cell Mol Med. 2010;14(11):2570\u201384. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01125.x.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"3383_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.dld.2009.07.018","volume":"42","author":"V Zamora","year":"2010","unstructured":"Zamora V, Cabanne A, Salanova R, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis. 2010;42(3):220\u20135. https:\/\/doi.org\/10.1016\/j.dld.2009.07.018.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"3383_CR13","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10613","volume":"22","author":"O Popa","year":"2021","unstructured":"Popa O, Taban SM, Pantea S, et al. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor\u00a02 and 5. Exp Ther Med. 2021;22(4):1179. https:\/\/doi.org\/10.3892\/etm.2021.10613.","journal-title":"Exp Ther Med"},{"issue":"8632","key":"3383_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/s0140-6736(89)91258-0","volume":"1","author":"EP Krenning","year":"1989","unstructured":"Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1(8632):242\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(89)91258-0.","journal-title":"Lancet"},{"issue":"2","key":"3383_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase\u00a03 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"16","key":"3383_CR16","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.Ccr-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0), Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2743.","journal-title":"Clin Cancer Res"},{"key":"3383_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1241724","volume":"14","author":"H Yao","year":"2023","unstructured":"Yao H, Hu G, Jiang C, et al. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms. Front Endocrinol (Lausanne). 2023;14:1241724. https:\/\/doi.org\/10.3389\/fendo.2023.1241724.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"3383_CR18","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1097\/js9.0000000000001080","volume":"110","author":"Z Wu","year":"2024","unstructured":"Wu Z, Shang G, Zhang K, Wang W, Fan M, Lin R. Combined the surgery, radiation, and chemotherapy for predicting overall survival in patients with gastroenteropancreatic neuroendocrine tumors. Int J Surg. 2024;110(4):2178\u201386. https:\/\/doi.org\/10.1097\/js9.0000000000001080.","journal-title":"Int J Surg"},{"issue":"5","key":"3383_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3390\/cancers14051119","volume":"14","author":"D Takayanagi","year":"2022","unstructured":"Takayanagi D, Cho H, Machida E, et al. Update on epidemiology, diagnosis, and biomarkers in gastroenteropancreatic neuroendocrine neoplasms. Cancers (Basel). 2022;14(5):1119.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"3383_CR20","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.cgh.2018.12.017","volume":"17","author":"MR Lee","year":"2019","unstructured":"Lee MR, Harris C, Baeg KJ, Aronson A, Wisnivesky JP, Kim MK. Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States. Clin Gastroenterol Hepatol. 2019;17(11):2212-2217.e2211. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.017.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3383_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s12020-023-03649-4","volume":"84","author":"F Panzuto","year":"2024","unstructured":"Panzuto F, Partelli S, Campana D, et al. Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian Association for Neuroendocrine Tumors (Itanet) national database. Endocrine. 2024;84(1):42\u20137. https:\/\/doi.org\/10.1007\/s12020-023-03649-4.","journal-title":"Endocrine"},{"key":"3383_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2022.07.015","volume":"129","author":"CM Heaphy","year":"2022","unstructured":"Heaphy CM, Singhi AD. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors. Hum Pathol. 2022;129:11\u201320. https:\/\/doi.org\/10.1016\/j.humpath.2022.07.015.","journal-title":"Hum Pathol"},{"issue":"3","key":"3383_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.123.265706","volume":"65","author":"JR Strosberg","year":"2024","unstructured":"Strosberg JR, Al-Toubah T, El-Haddad G, Reidy Lagunes D, Bodei L. Sequencing of somatostatin-receptor-based therapies in neuroendocrine tumor patients. J Nucl Med. 2024;65(3):340\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.265706.","journal-title":"J Nucl Med"},{"issue":"5","key":"3383_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101794","volume":"37","author":"N Fazio","year":"2023","unstructured":"Fazio N, La Salvia A. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: where are we in 2023? Best Pract Res Clin Endocrinol Metab. 2023;37(5):101794. https:\/\/doi.org\/10.1016\/j.beem.2023.101794.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3383_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102560","volume":"117","author":"A La Salvia","year":"2023","unstructured":"La Salvia A, Modica R, Rossi RE, et al. Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists. Cancer Treat Rev. 2023;117:102560. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102560.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"3383_CR26","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","volume":"13","author":"S Das","year":"2019","unstructured":"Das S, Al-Toubah T, El-Haddad G, Strosberg J. (177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019;13(11):1023\u201331. https:\/\/doi.org\/10.1080\/17474124.2019.1685381.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3383_CR27","unstructured":"European Medicines Agency. Lutathera (lutetium (177Lu) oxodotreotide) 370 MBq\/mL solution for infusion. 2025. Updated 03\/04\/2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lutathera. Accessed 11 Apr 2024."},{"key":"3383_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041110","author":"L Urso","year":"2023","unstructured":"Urso L, Nieri A, Uccelli L, et al. Lutathera\u00ae orphans: state of the art and future application of radioligand therapy with (177)Lu-DOTATATE. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15041110.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3383_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0290","volume":"5","author":"S Pusceddu","year":"2022","unstructured":"Pusceddu S, Prinzi N, Tafuto S, et al. Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors. JAMA Netw Open. 2022;5(2):e220290. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0290.","journal-title":"JAMA Netw Open"},{"key":"3383_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13072074","author":"F Panzuto","year":"2024","unstructured":"Panzuto F, Andrini E, Lamberti G, et al. Sequencing treatments in patients with advanced well-differentiated pancreatic neuroendocrine tumor (pNET): results from a large multicenter Italian cohort. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13072074.","journal-title":"J Clin Med"},{"issue":"7","key":"3383_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13146","volume":"34","author":"S Grozinsky-Glasberg","year":"2022","unstructured":"Grozinsky-Glasberg S, Davar J, Hofland J, et al. European neuroendocrine tumor society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol. 2022;34(7):e13146. https:\/\/doi.org\/10.1111\/jne.13146.","journal-title":"J Neuroendocrinol"},{"issue":"6","key":"3383_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13309","volume":"35","author":"A Rinke","year":"2023","unstructured":"Rinke A, Ambrosini V, Dromain C, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol. 2023;35(6):e13309. https:\/\/doi.org\/10.1111\/jne.13309.","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"3383_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13249","volume":"35","author":"H Sorbye","year":"2023","unstructured":"Sorbye H, Grande E, Pavel M, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35(3):e13249. https:\/\/doi.org\/10.1111\/jne.13249.","journal-title":"J Neuroendocrinol"},{"issue":"8","key":"3383_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13306","volume":"35","author":"F Panzuto","year":"2023","unstructured":"Panzuto F, Ramage J, Pritchard DM, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1\u2013G3. J Neuroendocrinol. 2023;35(8):e13306. https:\/\/doi.org\/10.1111\/jne.13306.","journal-title":"J Neuroendocrinol"},{"issue":"8","key":"3383_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland J, Falconi M, Christ E, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318. https:\/\/doi.org\/10.1111\/jne.13318.","journal-title":"J Neuroendocrinol"},{"issue":"12","key":"3383_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13343","volume":"35","author":"B Kos-Kudla","year":"2023","unstructured":"Kos-Kudla B, Castano JP, Denecke T, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35(12):e13343. https:\/\/doi.org\/10.1111\/jne.13343.","journal-title":"J Neuroendocrinol"},{"issue":"10","key":"3383_CR37","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","volume":"47","author":"J Strosberg","year":"2020","unstructured":"Strosberg J, Kunz PL, Hendifar A, et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47(10):2372\u201382. https:\/\/doi.org\/10.1007\/s00259-020-04709-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3383_CR38","unstructured":"AIOM\/ITANET. Linee guida NEOPLASIE NEUROENDOCRINE. In condivisione con It.a.net Italian Association for Neuroendocrine Tumours. Edizione 2021. 2021. https:\/\/www.iss.it\/documents\/20126\/8403839\/LG-311-Neoplasie-Neuroendocrine_agg2022. Accessed 11 Ap 2024."},{"key":"3383_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02448-6","author":"F Panzuto","year":"2024","unstructured":"Panzuto F, Albertelli M, De Rimini ML, et al. Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM). J Endocrinol Invest. 2024. https:\/\/doi.org\/10.1007\/s40618-024-02448-6.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"3383_CR40","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s11154-020-09581-6","volume":"22","author":"M Albertelli","year":"2021","unstructured":"Albertelli M, Dotto A, Di Dato C, et al. PRRT: identikit of the perfect patient. Rev Endocr Metab Disord. 2021;22(3):563\u201379. https:\/\/doi.org\/10.1007\/s11154-020-09581-6.","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"3383_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12325-023-02714-8","volume":"41","author":"N Fazio","year":"2024","unstructured":"Fazio N, Falconi M, Foglia E, et al. Optimising radioligand therapy for patients with gastro-entero-pancreatic neuroendocrine tumours: expert opinion from an Italian multidisciplinary group. Adv Ther. 2024;41(1):113\u201329. https:\/\/doi.org\/10.1007\/s12325-023-02714-8.","journal-title":"Adv Ther"},{"key":"3383_CR42","unstructured":"Kunz PL, Benson AB, Bodei L, et al. Abstract 142: The phase\u00a03 NETTER-1 study of 177 Lu-DOTATATE in patients with midgut neuroendocrine tumours: updated progression free survival analyses. Poster presented at the North American Neuroendocrine Tumor Society (NANETS) Annual Multidisciplinary Medical Symposium, Chicago, IL, USA; 2021, November 4 6, 2021."},{"key":"3383_CR43","volume-title":"Who classification of tumours of the digestive system","author":"FT Bosman","year":"2010","unstructured":"Bosman FT, Carneiro F, Hruban RH, Theise ND. Who classification of tumours of the digestive system, vol. 3. 4th ed. Lyon: IARC; 2010.","edition":"4"},{"key":"3383_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06725-7","author":"S Lastoria","year":"2024","unstructured":"Lastoria S, Rodari M, Sansovini M, et al. Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06725-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"3383_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1530\/erc-18-0424","volume":"26","author":"EA Carlsen","year":"2019","unstructured":"Carlsen EA, Fazio N, Granberg D, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26(2):227\u201339. https:\/\/doi.org\/10.1530\/erc-18-0424.","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"3383_CR46","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s00259-023-06166-8","volume":"50","author":"M Mitjavila","year":"2023","unstructured":"Mitjavila M, Jimenez-Fonseca P, Bell\u00f3 P, et al. Efficacy of [(177)Lu]lu-dotatate in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023;50(8):2486\u2013500. https:\/\/doi.org\/10.1007\/s00259-023-06166-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"3383_CR47","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1245\/s10434-022-12149-0","volume":"29","author":"JR Howe","year":"2022","unstructured":"Howe JR. Sequencing of therapies in progressive neuroendocrine tumors. Ann Surg Oncol. 2022;29(11):6501\u20133. https:\/\/doi.org\/10.1245\/s10434-022-12149-0.","journal-title":"Ann Surg Oncol"},{"key":"3383_CR48","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0206","author":"JR Eads","year":"2023","unstructured":"Eads JR, Halfdanarson TR, Asmis T, et al. Expert consensus practice recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer. 2023. https:\/\/doi.org\/10.1530\/ERC-22-0206.","journal-title":"Endocr Relat Cancer"},{"issue":"32","key":"3383_CR49","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/jco.23.01529","volume":"41","author":"J Del Rivero","year":"2023","unstructured":"Del Rivero J, Perez K, Kennedy EB, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J Clin Oncol. 2023;41(32):5049\u201367. https:\/\/doi.org\/10.1200\/jco.23.01529.","journal-title":"J Clin Oncol"},{"key":"3383_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13423","author":"A Lamarca","year":"2024","unstructured":"Lamarca A, Bartsch DK, Caplin M, et al. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024. https:\/\/doi.org\/10.1111\/jne.13423.","journal-title":"J Neuroendocrinol"},{"issue":"3_suppl","key":"3383_CR51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA588","volume":"42","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin DM, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase\u00a03 randomized NETTER-2 study. J Clin Oncol. 2024;42(3_suppl):LBA588. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.LBA588.","journal-title":"J Clin Oncol"},{"key":"3383_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ctrv.2016.01.005","volume":"44","author":"A Lamarca","year":"2016","unstructured":"Lamarca A, Elliott E, Barriuso J, et al. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause? Cancer Treat Rev. 2016;44:26\u201341. https:\/\/doi.org\/10.1016\/j.ctrv.2016.01.005.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"3383_CR53","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, et al. (177)Lu-dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase\u00a03 trial. Lancet Oncol. 2021;22(12):1752\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6.","journal-title":"Lancet Oncol"},{"key":"3383_CR54","unstructured":"U S Food & Drug Administration (FDA). LUTATHERA\u00ae (lutetium Lu 177 dotatate) injection, for intravenous use. Highlights of prescribing information. 2024. https:\/\/www.acessdata.fda.gov Accessed 3 Jul 2025."},{"key":"3383_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101378","author":"F Panzuto","year":"2025","unstructured":"Panzuto F, Cives M, Strosberg J. Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients? Lancet Reg Health Eur. 2025. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101378.","journal-title":"Lancet Reg Health Eur"},{"key":"3383_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16172993","author":"R Gujarathi","year":"2024","unstructured":"Gujarathi R, Tobias J, Abou Azar S, Keutgen XM, Liao CY. Peptide receptor radionuclide therapy versus capecitabine\/temozolomide for the treatment of metastatic pancreatic neuroendocrine tumors. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16172993.","journal-title":"Cancers (Basel)"},{"key":"3383_CR57","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2024.02.002","author":"G Santo","year":"2024","unstructured":"Santo G, Di Santo G, Virgolini I. Peptide receptor radionuclide therapy of neuroendocrine tumors: agonist, antagonist and alternatives. Semin Nucl Med. 2024. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.02.002.","journal-title":"Semin Nucl Med"},{"issue":"10","key":"3383_CR58","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2967\/jnumed.120.251512","volume":"62","author":"S Park","year":"2021","unstructured":"Park S, Parihar AS, Bodei L, et al. Somatostatin receptor imaging and theranostics: current practice and future prospects. J Nucl Med. 2021;62(10):1323\u20139. https:\/\/doi.org\/10.2967\/jnumed.120.251512.","journal-title":"J Nucl Med"},{"issue":"5","key":"3383_CR59","first-page":"311","volume":"8","author":"E Pauwels","year":"2018","unstructured":"Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands\u2014the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311\u201331.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"2","key":"3383_CR60","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40618-021-01642-0","volume":"45","author":"A Laffi","year":"2022","unstructured":"Laffi A, Spada F, Bagnardi V, et al. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis. J Endocrinol Invest. 2022;45(2):317\u201325. https:\/\/doi.org\/10.1007\/s40618-021-01642-0.","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"3383_CR61","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/rlu.0000000000004235","volume":"47","author":"ONY Lee","year":"2022","unstructured":"Lee ONY, Tan KV, Tripathi V, Yuan H, Chan WW, Chiu KWH. The role of 68 Ga-DOTA-SSA PET\/CT in the management and prediction of peptide receptor radionuclide therapy response for patients with neuroendocrine tumors: a systematic review and meta-analysis. Clin Nucl Med. 2022;47(9):781\u201393. https:\/\/doi.org\/10.1097\/rlu.0000000000004235.","journal-title":"Clin Nucl Med"},{"key":"3383_CR62","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","volume":"157","author":"M Pavel","year":"2021","unstructured":"Pavel M, \u0106wik\u0142a JB, Lombard-Bohas C, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase\u00a02 study results. Eur J Cancer. 2021;157:403\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2021.06.056.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3383_CR63","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/annonc\/mdw561","volume":"28","author":"S Faivre","year":"2017","unstructured":"Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase\u00a0III randomized study. Ann Oncol. 2017;28(2):339\u201343. https:\/\/doi.org\/10.1093\/annonc\/mdw561.","journal-title":"Ann Oncol"},{"issue":"6","key":"3383_CR64","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1009290.","journal-title":"N Engl J Med"},{"issue":"32","key":"3383_CR65","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1200\/jco.2016.68.0702","volume":"34","author":"JC Yao","year":"2016","unstructured":"Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase\u00a0III radiant-3 study. J Clin Oncol. 2016;34(32):3906\u201313. https:\/\/doi.org\/10.1200\/jco.2016.68.0702.","journal-title":"J Clin Oncol"},{"issue":"10022","key":"3383_CR66","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/s0140-6736(15)00817-x","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase\u00a03 study. Lancet. 2016;387(10022):968\u201377. https:\/\/doi.org\/10.1016\/s0140-6736(15)00817-x.","journal-title":"Lancet"},{"issue":"7","key":"3383_CR67","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/jco.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz PL, Graham NT, Catalano PJ, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023;41(7):1359\u201369. https:\/\/doi.org\/10.1200\/jco.22.01013.","journal-title":"J Clin Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03383-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03383-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03383-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:27Z","timestamp":1763132667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03383-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3383"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03383-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Salvatore Tafuto: has performed consultancy, has been a member of advisory boards, and has received fees from AAA, Novartis, Ipsen, Esteve, Deciphera, Boehringer. Secondo Lastoria has received fees for participating on Advanced Accelerator Applications (AAA) advisory boards. Lorenzo Antonuzzo has received payment or honoraria for lectures and presentation from AstraZeneca, Roche, Astellas, Novartis, MSD, BMS, Ipsen, Merck Serono, Amgen, Bayer; Support for attending meetings and\/or travel grants\u00a0from AstraZeneca, Novartis, Ipsen, Merck Serono, his institution received research funding from Novartis, AstraZeneca. Sara Cingarlini has received speaker\u2019s fees from\u00a0Novartis, Pierre Fabre, and Bristol Myers. Mauro Cives has performed consultation for AAA \u2013 Novartis, Advanz, Esteve, Camurus, Harbour Biomed, Harpoon Therapeutics, and has received speaker\u2019s fees from AAA \u2013 Novartis and Ipsen. Diego Ferone has been a consultant for AAA \u2013 Novartis, Camurus, Recordati RD, and received speaker\u2019s fees or research grants from Camurus, Recordati RD. Angelina Filice has received speaker\u2019s fees from Novartis and has performed consultations for Novartis. Dario. Giuffrida attended meetings and\/or received travel grants from\u00a0Novartis, Ipsen, Merck Serono, his institution received research funding novartis. Marco Maccauro has received speaker\u2019s fees from AAA \u2013 Novartis and Boston Scientific. Nicola Fazio declares financial Interests related to Astellas, Advisory Board, Personal; Astellas, Invited Speaker, Personal; Ipsen, Advisory Board, Personal; ITM, Advisory Board, Personal; Merck, Advisory Board, Personal; Novartis, Other, Personal, Steering committee; Novartis, Invited Speaker, Personal; Novartis, Advisory Board, Personal; Astellas, Local PI, Institutional, Financial interest; Boehringer, Local PI, Institutional, Financial interest; Fibrogen, Local PI, Institutional, Financial interest; Ipsen, Local PI, Institutional, Financial interest; Ipsen, Research Grant, Institutional, Financial interest; ITM, Local PI, Institutional, Financial interest; Merck, Research Grant, Institutional, Financial interest: MSD, Local PI, Institutional, Financial interest; Novartis, Research Grant, Institutional, Financial interest; Revolution medicine, Local PI, Institutional, Financial interest and non-financial interests related to AIOM, Other, Internal reviewer of NET guidelines; ENETS, Other, President elect; ESMO, Other, Member of the NET Faculty; ITANET, Other, Member of the scientific board; SPARC Europe, Other, Steering committee. Francesco Panzuto, Davide Campana, Dario Giuffrida, Stefano Partelli declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}